BRA
GILD icon

Bender Robert & Associates’s Gilead Sciences GILD Stock Holding History

Bender Robert & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,713
Closed -$1.28M – 55
2024
Q2 		$1.28M Buy
+18,713
New +$1.25M 0.28% 26

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bender Robert & Associates's GILD Position: Q1 2026 in Review

Bender Robert & Associates held its Gilead Sciences (GILD) position steady in Q1 2026 at 2,819 shares worth $393K. The position accounts for 0.09% of the portfolio, ranked #34.

Bender Robert & Associates first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $12.6M in Q2 2015. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Bender Robert & Associates held 2,819 shares of Gilead Sciences worth $393K as of Q1 2026.
  • Bender Robert & Associates left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.09% of Bender Robert & Associates's portfolio in Q1 2026, its #34 holding.
  • Bender Robert & Associates first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
  • Bender Robert & Associates's Gilead Sciences position peaked at $12.6M in Q2 2015.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Bender Robert & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.